Company news

Neuren Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Q3 2024 update

November 6, 2024

PRV sold for US$150m - Neuren to receive one third

November 5, 2024

DAYBUE receives marketing authorization in Canada

October 16, 2024

NEU continues PMS P3 preparations after positive FDA meeting

October 6, 2024

Phase 2 trial shows significant improvements in Angelman

August 9, 2024

Q2 2024 update

August 7, 2024

Phase 2 trial shows significant improvements in Pitt Hopkins

May 27, 2024

DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

May 9, 2024

Q1 2024 quarterly activity and cash flow report

April 24, 2024

Trofinetide accepted for Priority Review by Health Canada

April 23, 2024

Neuren reports profit of $157 million for 2023

February 29, 2024

Appendix 4E and 2023 full year accounts

February 29, 2024

DAYBUE net sales US$87.1 million in Q4 2023

February 27, 2024

Comment on research report

February 16, 2024

Q4 2023 Appendix 4C Cash Flow Report

January 31, 2024

Q4 2023 quarterly activity report

January 31, 2024

Completion of enrolment in Neuren's Angelman P2 trial

December 19, 2023

Investor presentation, 18 December 2023

December 17, 2023

P2 trial shows significant improvements in Phelan-McDermid

December 17, 2023

Neuren completes enrolment in Pitt Hopkins Phase 2 trial

December 4, 2023

DAYBUE net sales US$66.9 million in Q3 2023

November 2, 2023

Q3 2023 quarterly activity and cash flow report

October 19, 2023

S&P DJI Announces September 2023 Quarterly Rebalance

September 1, 2023

Q2 2023 quarterly activity and cash flow report

July 30, 2023

Neuren receives US$100m for expanded DAYBUE agreement

July 27, 2023

Neuren and Acadia expand global partnership for trofinetide

July 13, 2023

Neuren completes enrolment in Phelan-McDermid Phase 2 trial

June 29, 2023

Neuren opens first site in US for Prader-Willi Phase 2 trial

June 28, 2023

Neuren receives US$40m milestone payment

June 7, 2023

Q1 2023 quarterly activity and cash flow report

April 27, 2023

DAYBUE (trofinetide) launched in US - Neuren earns US$40m

April 18, 2023

FDA approves Daybue - the first treatment for Rett syndrome

March 12, 2023

Neuren reports 2022 full-year results

February 23, 2023

Appendix 4E and 2022 full year accounts

February 23, 2023

Q4 2022 quarterly activity and cash flow report

January 30, 2023

Prader-Willi syndrome IND for NNZ-2591 approved by FDA

January 22, 2023

Neuren submits IND & first patients complete Phase 2 trials

December 22, 2022

Q3 2022 quarterly activity and cash flow report

October 26, 2022

Neuren receives US$10 million milestone payment

October 19, 2022

Rett Syndrome NDA accepted for Priority Review by FDA

September 12, 2022

S&P DJI Announces September 2022 Quarterly Rebalance

September 2, 2022

Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

August 7, 2022

Quarterly Activities/Appendix 4C Cash Flow Report

July 29, 2022

Acadia submits Rett Syndrome New Drug Application to the FDA

July 19, 2022

Neuren commences Phase 2 trial of NNZ-2591 in Angelman

July 11, 2022

Neuren appoints Chief Medical Officer in United States

July 8, 2022

FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial

March 24, 2022

FDA approval for Phelan-McDermid IND and Phase 2 trial

March 22, 2022

Ethics approval for Angelman Phase 2 trial in Australia

March 10, 2022

S&P DJI Announces March 2022 Quarterly Rebalance

March 4, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 91 decks. Every deck is listed under its year.